Mingdu Zhiyun (Zhejiang) Technology

About Mingdu Zhiyun (Zhejiang) Technology

Mingdu Zhiyun (Zhejiang) Technology Co., Ltd., established in 2017, operates as a specialized digital transformation service provider for the life sciences and biopharmaceutical industries in China. The company was founded by Chairman Ge Yafei, who previously served as chairman and president of the publicly listed company Dian Diagnostics and chairman of Aubo Robotics. His background in corporate management and smart manufacturing informed his decision to launch Mingdu Zhiyun, driven by a recognition of the potential for digitalization within China's biopharmaceutical sector.

The firm targets pharmaceutical and biotechnology companies, offering a comprehensive suite of digital solutions that span the entire lifecycle of a drug, from research and development to production and logistics. Its business model is centered on providing proprietary software and integrated systems that help clients navigate complex regulatory environments, improve operational efficiency, and accelerate product development. The company serves a notable client base that includes major domestic pharmaceutical groups like Shanghai Pharma, Livzon Pharmaceutical Group, and China Resources 999.

Mingdu Zhiyun's core offering is a full-stack digital product matrix designed to address key operational challenges in the pharmaceutical sector. This includes the MSP Mingdu Scientific Platform, which features an Electronic Lab Notebook (ELN) and Scientific Data Management System (SDMS) to digitize R&D processes. For manufacturing, its integrated platform addresses production, quality control, and warehousing, aiming to reduce reliance on manual operations and improve batch release times. The company also provides intelligent logistics solutions to create an integrated system from the workshop to the warehouse. These products are positioned as domestic alternatives to foreign software from firms like Siemens and VEEVA, addressing the need for secure and autonomous core industrial software within China's pharmaceutical industry. The company has received venture capital backing from investors such as CASH Capital, Zheshang Venture Capital, and various arms of the China Merchants Group.